Newsroom

The latest news and updates from Oncopeptides

In the spotlight

Oncopeptides publishes Q1 report 2026

Latest press releases

Bulletin from the Annual General Meeting in Oncopeptides

Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma

CompanyInvestor

COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Oncopeptides publishes Q1 report 2026

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

InvestorScience

Invitation to presentation of the Q1 report 2026

Oncopeptides publishes the 2025 Annual Report

Latest news

Oncopeptalks: Q1 report

Redeye interviews Oncopeptides CEO Sofia Heigis

Launching: Oncopeptalks as a podcast

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

The final Oncopeptalks

In the latest, and “final”, Oncopeptalks, Sofia covers, among other things, congress season, and David provides some updates from the communications side – including that Oncopeptalks will take on a new shape in the future.

Upcoming events

7th European Myeloma Network Meeting

Clarion Congress Hotel, Prague, Czech Republic

12th World Congress on Controversies in Multiple Myeloma (COMy)

Paris, France & Online

EHA Congress 2026

The European Hematology Association (EHA)

Stockholm, Sweden